Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease (Diversity1) - Trial SLCTR_2018_029
Access comprehensive clinical trial information for SLCTR_2018_029 through Pure Global AI's free database. This Phase 3 trial is sponsored by Gilead Sciences, Inc and is currently Recruiting. The study focuses on Crohn's Disease.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
SLCTR_2018_029
Phase 3
Recruiting
Trial Details
Sri Lanka Clinical Trials Registry • SLCTR_2018_029
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease (Diversity1)
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease
Study Focus
Interventional
Sponsor & Location
Gilead Sciences, Inc
Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czech Republic, France, Georgia, Germany, Gr
Timeline & Enrollment
Phase 3
Jul 31, 2019
N/A
ICD-10 Classifications
Crohn disease, unspecified
Other Crohn disease
Crohn disease of large intestine
Crohn disease [regional enteritis]
Crohn disease of small intestine
Data Source
Sri Lanka Clinical Trials Registry
SLCTR_2018_029
Non-Device Trial